Vergote I, du Bois A, Floquet A, et al. - Whether pazopanib maintenance in patients with newly diagnosed advanced ovarian cancer (AOC) after first-line chemotherapy would be efficacious, safe and tolerable, was investigated in the AGO-OVAR16 study. Researchers randomly assigned (1:1) a total of 940 patients with histologically proved AOC, FIGO stage II–IV, to receive either 800 mg pazopanib once daily or placebo for up to 24 months, until disease progression, toxicity, withdrawal of consent, or death. The investigator-evaluated progression-free survival [PFS] was the primary endpoint, which was met and earlier reported. In this study, the findings of the final analyses of overall survival (OS) were described. According to the findings, PFS was prolonged as a result of treatment with pazopanib, but no improvement in median OS was evident.